Tuesday, November 17, 2026

MOLCURE Raises 800 Million Yen in Funding to Accelerate Joint Development with Major Pharmaceutical Companies

MOLCURE, an AI-based new drug development company, has completed a total of 800 million yen in funding through a third-party allocation of new shares with Jafco Group, STRIVE, SBI Investment, Japan Post Capital, GMO Venture Partners, and Nippon Chemiphar as the underwriters. Going forward, the company will promote joint drug discovery pipeline development with major pharmaceutical companies in Japan and overseas, and further accelerate its business development mainly in the global arena.

Background and Purpose of Fundraising

It is said that there are more than 30,000 diseases for which there are no effective treatments, making the development of new drugs extremely important. However, the difficulty of drug discovery in the pharmaceutical industry is increasing year by year, and development efficiency is declining. Since it takes about 10 years and a huge cost of about 100 billion yen (*1) for a pharmaceutical company to bring a drug to the market, new technologies and development methods are needed.

The biopharmaceutical molecule design technology provided by MOLCURE can automatically perform large-scale screening and molecule design using AI and robotics, and compared to existing methods, can streamline the discovery cycle of drug candidate molecules to less than one-tenth, discover more than 10 times more new drug It is also possible to discover 10 times more new drug candidates and design molecules with superior properties that are difficult to discover using conventional methods. Currently, the company is using this technology to develop new drugs in partnership with pharmaceutical companies.

In particular, in the joint drug discovery pipeline development conducted with a pharmaceutical company in 2021, the company succeeded in designing a large number of molecules with 100 times more binding power than existing biotechnological experiment-driven methods, and also succeeded in designing molecules that are effective against a certain drug target for the first time in the world, This is the world's first success in designing molecules that are effective against a certain drug target, and is a major achievement in the case of AI-based drug discovery.

The company will use the funding to accelerate joint development with major pharmaceutical companies and global expansion, and promote business development to improve the quality of life (QOL) of patients.

1 [citation needed] Nat Rev Drug Discov. 2010 Mar;9(3):203-14.
"How to improve R&D productivity: the pharmaceutical industry's grand challenge." 

Become the de facto standard for AI utilization by domestic and foreign pharmaceutical companies in partnership

The technology provided by MOLCURE is supported by its ability to search for an overwhelmingly large number of superior drug molecules and the high-quality expertise in AI x biopharmaceutical development provided by a group of top researchers in the industry. To date, MOLCURE has been used in 10 projects by a cumulative total of 7 major pharmaceutical companies and major pharmaceutical biotech companies, including Twist Bioscience (U.S.) and Nippon Chemiphar (*2).
2 Examples of partners engaged in joint drug discovery pipeline development as of August 18, 2021

The following press release, dated July 27, 2021, from Dr. Emily Leproust, CEO and co-founder of Twist Bioscience, regarding joint drug discovery pipeline development (https://molcure.com/2021/07/27/twist-bioscience-jp/(Comments have been received from the following.

Twist Bioscience continues to innovate and incorporate cutting-edge antibody discovery and optimization methodologies into our processes, and MOLCURE's AI technology provides leverage for our proprietary antibody discovery and optimization efforts and technologies, enabling us to enhance our internal antibody pipeline. and enhance our in-house antibody drug pipeline. Their AI technology, together with our antibody drug library and NGS sequencing data, will enable us to explore additional lead antibodies. We look forward to incorporating the lead antibodies from this collaboration into our internal pipeline."

About Twist Bioscience, Inc.

Twist Bioscience, a fast-growing leader in synthetic biology and genomics, has developed a DNA synthesis platform that is a disruptive innovation for the industrialization of biotechnology. At the core of this platform is a proprietary state-of-the-art technology that "writes" DNA onto silicon chips to produce synthetic DNA, which Twist leverages to produce a wide range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS), and antibody libraries for drug discovery and development. based products, including synthetic genes, tools for next-generation sequencing (NGS), and antibody libraries for drug discovery and development. The company is also exploring the long-term potential of digital data storage in DNA and biologics drug discovery.Twist will manufacture products for use in a variety of industries, including healthcare, industrial chemistry, agriculture, and academic research.

About Nippon Chemiphar

Founded in 1950, Nippon Chemiphar is a company engaged in the business of prescription pharmaceuticals, clinical diagnostics, and healthcare. The company has three growth strategies: "generic drugs," "alkalizing agents," and "self-developed drug discovery," and aims to expand the results of these strategies domestically and internationally. In the area of in-house drug discovery, the company is engaged in the development of breakthrough new drugs and drug repositioning of existing drugs through "venture-type drug discovery research" focused on exploratory research, and has recently succeeded in identifying several promising candidate compounds for new drug development. 

The company will continue to utilize cutting-edge technologies such as AI to discover further new drug candidates, improve the quality of drug molecules, and realize more efficient drug discovery research.

Underwriter's Comment

Mr. Atsushi Fujii, Partner, Jafco Group K.K.

MOLCURE is a team of talented members who share a strong desire to "realize a world where there is a special medicine for every disease" and who share the same passion in the fields of biotechnology, AI, and robotics. Our drug design platform has already reached the point where it can create drug candidates with performance superior to that of manually developed drugs, and we have decided to invest in MOLCURE in order to take on the challenge of updating drug development together with MOLCURE. We are confident that MOLCURE will grow globally as an AI drug discovery startup from Japan.

Ms. Natsumi Negishi, Partner, STRIVE Corporation

As in other industries, innovative AI-based methods are rapidly spreading in drug discovery, especially in the U.S. MOLCURE has been developing AI-based technologies since its founding in 2013 and is a leading AI drug discovery company in Japan. We have assembled talented members in the fields of evolutionary molecular engineering, AI, and robotics, and have already produced promising drug candidate molecules in collaboration with our clients. We have decided to invest in this company because we strongly feel the market expansion and our company's potential in the future. We hope that more new drugs will be created through our platform in the future.

Mr. Makoto Hasegawa, Manager, Investment Department, SBI Investment Co.

MOLCURE possesses high-level proprietary technologies in the fields of biotechnology, robotics, and AI. We have decided to invest in MOLCURE because we believe that the combination of these technologies has the potential to bring a breakthrough in drug development, which is becoming increasingly difficult year by year, by improving the efficiency of drug candidate molecule search. We are very pleased to be working with MOLCURE through this investment, and we hope that this technology will lead to the creation of innovative drugs that satisfy unmet medical needs as soon as possible.

Mr. Hiroki Yoshioka, Senior Associate, Investment Division, Japan Post Capital Co.

As there are still many diseases for which there is no cure, we believe that MOLCURE's biopharmaceutical development platform will contribute to the faster discovery of new treatments and new drug candidates that have not been found using conventional methods. We hope that MOLCURE, together with its many pharmaceutical partners, will achieve business growth and make more diseases treatable in the future.

Mr. Masahide Yasumoto, Director, Executive Officer, General Manager of Corporate Planning Department, Nippon Chemiphar Co.

We have been taking an equity stake in MOLCURE since November 2018 with the aim of developing breakthrough drugs for patients suffering from diseases for which there are still no adequate treatments. We have launched an initiative to innovate drug discovery research methods by integrating the company's AI drug discovery system with our drug discovery research infrastructure, and are currently conducting joint research in specific drug discovery target areas. We expect that MOLCURE's business growth and efforts to form a business alliance with us will be further accelerated by this further large-scale fundraising.

About MOLCURE Corporation

name of companyMOLCURE Corporation
EstablishmentMay 2013
capital stockAIRBIC A07, 7-7 Shinkawasaki, Saiwai-ku, Kawasaki-shi, Kanagawa, Japan
representativeRepresentative Director: Takashi Ogawa
Business OverviewDevelopment and provision of a drug discovery platform that integrates artificial intelligence, evolutionary molecular engineering, and experimental automation for peptide and antibody molecular design.
uniform resouce locatorhttps://molcure.com
PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。